Self-Assembled Polydopamine Nanoparticles Improve Treatment in Parkinson's Disease Model Mice and Suppress Dopamine-Induced Dyskinesia

Although Levodopa (L-DOPA), a dopamine precursor, exhibits a high risk of dyskinesia, it remains the primary treatment in Parkinson's disease (PD), a progressive neurodegenerative disorder. In this study, we designed poly(L-DOPA)-based self-assembly nanodrug (NanoDOPA) from amphiphilic block copolymer possessing poly(L-DOPA(OAc)2), which is a precursor of L-DOPA as a hydrophobic segment, for treatment in a PD model mouse. Under physiological enzyme treatment, the poly(L-DOPA(OAc)2) in the block copolymer was hydrolyzed to liberate L-DOPA gradually. Using the MPTP-induced PD mouse model, we observed that mice treated with NanoDOPA demonstrated significantly improve PD symptoms compared to the L-DOPA treatment. Interestingly, the NanoDOPA treatment did not cause the dyskinesia symptoms, which was clearly observed in the L-DOPA-treated mice. Furthermore, NanoDOPA exhibited remarkably lower toxicity in vitro compared to L-DOPA, in addition with no noticeable NanoDOPA toxicity observed in the treated mice. These results suggested that self-assembly NanoDOPA is a promising therapeutic in the treatment of PD.